vimarsana.com

Latest Breaking News On - Specialty clinical ophthalmology - Page 1 : vimarsana.com

Belite Bio Presented 18-Month Interim Data from a 24-Month Phase 2 Study of Tinlarebant in Adolescent Stargardt Disease at the 2023 ARVO Meeting

25.04.2023 - Tinlarebant (aka LBS-008) continues to be safe and well tolerated in adolescent Stargardt Disease (STGD1) subjects at the 18-month time pointA continued trend of slowing expansion of autofluorescence was observedThe growth rate of incident atrophic . Seite 1

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.